CING
Price
$3.79
Change
+$0.01 (+0.26%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
21.25M
RXRX
Price
$4.72
Change
+$0.09 (+1.94%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
2.02B
40 days until earnings call
Interact to see
Advertisement

CING vs RXRX

Header iconCING vs RXRX Comparison
Open Charts CING vs RXRXBanner chart's image
Cingulate
Price$3.79
Change+$0.01 (+0.26%)
Volume$300
Capitalization21.25M
Recursion Pharmaceuticals
Price$4.72
Change+$0.09 (+1.94%)
Volume$248.06K
Capitalization2.02B
CING vs RXRX Comparison Chart in %
Loading...
CING
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CING vs. RXRX commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CING is a Buy and RXRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (CING: $3.79 vs. RXRX: $4.63)
Brand notoriety: CING and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CING: 39% vs. RXRX: 214%
Market capitalization -- CING: $21.25M vs. RXRX: $2.02B
CING [@Biotechnology] is valued at $21.25M. RXRX’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CING’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • CING’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, CING is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CING’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • CING’s TA Score: 4 bullish, 3 bearish.
  • RXRX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both CING and RXRX are a good buy in the short-term.

Price Growth

CING (@Biotechnology) experienced а +7.67% price change this week, while RXRX (@Biotechnology) price change was -6.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +51.46%.

Reported Earning Dates

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.02B) has a higher market cap than CING($21.2M). CING YTD gains are higher at: -23.124 vs. RXRX (-31.509). CING has higher annual earnings (EBITDA): -17.21M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. CING (8.9M). CING has less debt than RXRX: CING (6.58M) vs RXRX (88.1M). RXRX has higher revenues than CING: RXRX (64.5M) vs CING (0).
CINGRXRXCING / RXRX
Capitalization21.2M2.02B1%
EBITDA-17.21M-583.64M3%
Gain YTD-23.124-31.50973%
P/E Ratio0.03N/A-
Revenue064.5M-
Total Cash8.9M525M2%
Total Debt6.58M88.1M7%
TECHNICAL ANALYSIS
Technical Analysis
CINGRXRX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 18 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CING
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDIKX50.96N/A
N/A
Fidelity Diversified International K
RIEIX13.11N/A
N/A
RBC International Equity I
SILVX18.42N/A
N/A
SGI US Large Cap Equity I
CDOYX42.56N/A
N/A
Columbia Dividend Opportunity Inst3
BAHAX17.98N/A
N/A
Brown Advisory WMC Strat Eurp Eq Adv

CING and

Correlation & Price change

A.I.dvisor indicates that over the last year, CING has been loosely correlated with ABCL. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CING jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CING
1D Price
Change %
CING100%
-1.04%
ABCL - CING
35%
Loosely correlated
-2.52%
BEIGF - CING
29%
Poorly correlated
N/A
ELVN - CING
29%
Poorly correlated
-3.28%
RXRX - CING
28%
Poorly correlated
-5.12%
SLNO - CING
28%
Poorly correlated
-2.76%
More